---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-217037"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2026-05-11T20:58:18+00:00"
generated_at: "2026-05-11T21:01:58.248662+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion Q1 net loss $12.4M; cash $45.1M; icovamenib Phase II T2D data due Q4 2026

## Summary
- Net loss $12.4M ($1.6M SBC) vs $29.3M in Q1 2025; cash, equivalents & restricted cash $45.1M at Mar 31, 2026; runway into Q1 2027.
- R&D expenses $9.1M (down from $22.9M YoY); G&A $3.7M (down from $6.8M).
- Icovamenib chronic tox studies completed; Phase II T2D trials COVALENT-211/-212 dosing; topline 26-week data expected Q4 2026.
- Phase II T1D COVALENT-112: 52% C-peptide AUC increase at week 12 (200mg); preservation through week 52; plan for investigator-sponsored trial.
- Phase I GLP-1 obesity trial (BMF-650, GLP-131) ongoing; initial 28-day weight data expected Q2 2026.

## SEC filing metadata
- accession: 0001193125-26-217037
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2026-05-11T20:58:18+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312526217037/0001193125-26-217037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312526217037/bmea-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-217037
- JSON: https://secwatch.observer/filing/0001193125-26-217037.json
- Plain text: https://secwatch.observer/filing/0001193125-26-217037.txt

## Key facts
- Earnings Releases
  Biomea Fusion, Inc. reported first quarter ended March 31, 2026 results: net income net loss of $12.4 million.
  - Period: first quarter ended March 31, 2026
  - Net income: net loss of $12.4 million
  - Result: reported results
  source text: Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840439/000119312526217037/0001193125-26-217037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.